Treatment of myelodysplastic syndromes with retinoic acid and 1 alpha-hydroxy-vitamin D3 in combination with low-dose ara-C is not superior to ara-C alone. Results from a randomized study. The Scandinavian Myelodysplasia Group (SMG) |
| |
Authors: | Eva Hellstr m,Karl-Henrik Robert,Jan Samuelsson,Christina Lindemalm,Gunnar Grimfors,Eva Kimby,Gunnar
berg,Ingemar Winqvist,Rolf Billstr m,Jan Carneskog,Magnus Dahl n,Mette Stockner,Finn Wisl ff,Ingunn Dybedal,Inger-Marie Dahl, ke
st |
| |
Affiliation: | Department of Medicine, Huddinge Hospital, Stockholm, Sweden. |
| |
Abstract: | 63 evaluable patients with myelodysplastic syndromes (MDS) and 15 with acute myelogenous leukemia (AML) were randomized between low-dose ara-C (arm A) and low dose ara-C in combination with 13-cis-retinoic acid (13-CRA) and 1 alpha-hydroxy-vitamin D3 (1 alpha D3) (arm B). 69 patients were evaluable and 18 (26.1%) responded to therapy. The addition of 13-CRA and 1 alpha D3 had no positive influence on survival of the patients, remission rates or duration of remissions. 12/27 patients in arm A and 6/29 patients in arm B progressed from MDS to AML during the course of the study (p = 0.0527). Arm B gave significantly more side-effects than arm A (p = 0.005). Therapeutic effects of 13-CRA and 1 alpha D3 on MDS is not supported by this study. However, an inhibiting effect on AML development in some MDS subgroups cannot be excluded. |
| |
Keywords: | myelodysplastic syndromes low-dose ara-C 13-cis-retinoic acid 1α hydroxy-vitamin D3 |
|
|